Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

17.42 -0.84 (-4.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
Analyst Ratings For Apellis Pharmaceuticals
Over the past 3 months, 8 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.... 
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan... 
Via Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
Cramer Likes DraftKings, Skyworks, And These Automakers
On CNBC's "Mad Money Lightning Rou... 
Via Benzinga
Better Pharmaceutical Stock: Apellis or Novartis?
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments. 
Via Talk Markets
Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ: 
Via Benzinga
60 Biggest Movers From Friday
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86. The U.S. has... 
Via Benzinga
Topics Stocks
What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
8 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today
Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results. 
Via InvestorPlace
Dow Eyes Fifth-Straight Skid, Another Weekly Drop
The Dow Jones Industrial Index is giving up its earlier gains, last seen down 149 points, as investors fail to shake off the economic uncertainty that's blanketed the holiday-shortened week. 
Via Talk Markets
Topics Stocks
Why Apellis Pharmaceutical Shares Are Plunging Today
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge
Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the... 
Via Benzinga
Topics Stocks
41 Stocks Moving In Friday's Mid-Day Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
Here's Why Iveric Bio Stock Is Rocketing Higher Today
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program. 
Via The Motley Fool
ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio
IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. 
Via InvestorPlace
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
Conflicting clinical trial results for the company's lead candidate are to blame. 
Via The Motley Fool
Why IVERIC Bio Shares Are Soaring Today
IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S.... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.